IO Biotech IncNASDAQ:IOBT
- LAST PRICE0.7079
- TODAY'S CHANGE (%)0.0259 (3.7977%)
- Bid / Lots0.7125/ 50
- Ask / Lots0.7500/ 25
- Open / Previous Close0.7220 / 0.6820
- Day Range
- 52 Week Range
- Volume1,182,609
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IOBT |
|---|---|---|
| 09:32 ET | 9502 | 0.73 |
| 09:33 ET | 8700 | 0.74 |
| 09:37 ET | 6500 | 0.77 |
| 09:39 ET | 194 | 0.76 |
| 09:42 ET | 15628 | 0.711 |
| 09:44 ET | 210 | 0.7465 |
| 09:48 ET | 500 | 0.75 |
| 09:50 ET | 1500 | 0.760811 |
| 09:51 ET | 3000 | 0.75 |
| 09:53 ET | 3750 | 0.7679 |
| 09:55 ET | 10897 | 0.7569 |
| 10:02 ET | 200 | 0.75 |
| 10:04 ET | 1840 | 0.766 |
| 10:08 ET | 100 | 0.765 |
| 10:09 ET | 2458 | 0.7659 |
| 10:11 ET | 2108 | 0.764499 |
| 10:13 ET | 3600 | 0.768 |
| 10:15 ET | 675 | 0.76999 |
| 10:20 ET | 1100 | 0.7699 |
| 10:22 ET | 5400 | 0.77 |
| 10:24 ET | 3045 | 0.7675 |
| 10:26 ET | 260 | 0.767501 |
| 10:27 ET | 690 | 0.761 |
| 10:29 ET | 1056 | 0.76014 |
| 10:31 ET | 1000 | 0.7555 |
| 10:33 ET | 1000 | 0.7555 |
| 10:38 ET | 915 | 0.7605 |
| 10:54 ET | 1100 | 0.7604 |
| 10:58 ET | 2000 | 0.7543 |
| 11:00 ET | 1012 | 0.75 |
| 11:16 ET | 500 | 0.7599 |
| 11:20 ET | 3755 | 0.76 |
| 11:21 ET | 132 | 0.7575 |
| 11:25 ET | 102087 | 0.75 |
| 11:27 ET | 18474 | 0.74 |
| 11:56 ET | 1100 | 0.74 |
| 11:57 ET | 100 | 0.736 |
| 11:59 ET | 149665 | 0.7055 |
| 12:01 ET | 5300 | 0.701 |
| 12:03 ET | 9842 | 0.702 |
| 12:10 ET | 3599 | 0.7169 |
| 12:14 ET | 1450 | 0.72 |
| 12:17 ET | 121292 | 0.7331 |
| 12:21 ET | 300 | 0.72 |
| 12:28 ET | 239 | 0.7179 |
| 12:32 ET | 200 | 0.7325 |
| 12:33 ET | 5151 | 0.737 |
| 12:35 ET | 2950 | 0.7401 |
| 12:37 ET | 10100 | 0.737 |
| 12:44 ET | 100 | 0.7401 |
| 12:55 ET | 400 | 0.7382 |
| 12:57 ET | 32814 | 0.725 |
| 01:00 ET | 1500 | 0.71 |
| 01:02 ET | 799 | 0.715 |
| 01:04 ET | 900 | 0.7101 |
| 01:06 ET | 400 | 0.7102 |
| 01:08 ET | 1000 | 0.73 |
| 01:13 ET | 8350 | 0.731 |
| 01:15 ET | 200 | 0.7126 |
| 01:18 ET | 400 | 0.7126 |
| 01:20 ET | 700 | 0.7126 |
| 01:24 ET | 5000 | 0.727999 |
| 01:26 ET | 300 | 0.72 |
| 01:29 ET | 5783 | 0.7165 |
| 01:31 ET | 599 | 0.7165 |
| 01:36 ET | 400 | 0.7128 |
| 01:38 ET | 200 | 0.7165 |
| 01:40 ET | 2325 | 0.72 |
| 01:42 ET | 100 | 0.72 |
| 01:44 ET | 800 | 0.73563 |
| 01:45 ET | 2000 | 0.74 |
| 01:49 ET | 1000 | 0.74 |
| 01:51 ET | 9727 | 0.72 |
| 01:56 ET | 100 | 0.73 |
| 02:02 ET | 120 | 0.744399 |
| 02:05 ET | 596 | 0.73 |
| 02:14 ET | 400 | 0.738 |
| 02:18 ET | 300 | 0.7381 |
| 02:20 ET | 900 | 0.7381 |
| 02:21 ET | 1000 | 0.7479 |
| 02:32 ET | 300 | 0.7441 |
| 02:34 ET | 1000 | 0.748 |
| 02:36 ET | 1783 | 0.748 |
| 02:38 ET | 700 | 0.748 |
| 02:39 ET | 6974 | 0.74 |
| 02:43 ET | 676 | 0.748 |
| 02:48 ET | 299 | 0.731 |
| 02:50 ET | 1680 | 0.7289 |
| 02:54 ET | 2180 | 0.7202 |
| 02:56 ET | 4339 | 0.73 |
| 02:57 ET | 4000 | 0.7202 |
| 02:59 ET | 1000 | 0.7202 |
| 03:01 ET | 82359 | 0.7027 |
| 03:03 ET | 600 | 0.7028 |
| 03:06 ET | 99405 | 0.7023 |
| 03:08 ET | 1700 | 0.703 |
| 03:10 ET | 75375 | 0.7 |
| 03:12 ET | 24774 | 0.71 |
| 03:14 ET | 1686 | 0.727 |
| 03:15 ET | 15397 | 0.705 |
| 03:17 ET | 2620 | 0.7001 |
| 03:19 ET | 13900 | 0.7001 |
| 03:21 ET | 10763 | 0.701 |
| 03:28 ET | 1900 | 0.7085 |
| 03:33 ET | 800 | 0.705 |
| 03:35 ET | 400 | 0.705 |
| 03:37 ET | 3764 | 0.705 |
| 03:39 ET | 1764 | 0.7052 |
| 03:48 ET | 10226 | 0.705 |
| 03:51 ET | 44056 | 0.6902 |
| 03:53 ET | 8450 | 0.714 |
| 03:57 ET | 1544 | 0.7201 |
| 04:00 ET | 134162 | 0.7079 |
Nov 12, 2024
DJ IO Biotech Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 11:31AM ET on Tuesday Nov 12, 2024 by Dow Jones
11:31AM ET on Tuesday Nov 12, 2024 by Dow JonesPress Release: IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights, from 7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:05AM ET on Tuesday Nov 12, 2024 by Dow JonesIO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights, from 7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
IO Biotech Announces Participation in Upcoming Investor Conferences, from 4:05PM ET on Monday Nov 11, 2024 by Dow Jones
4:05PM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA(R) Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study, from 10:00AM ET on Thursday Nov 07, 2024 by Dow Jones
10:00AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IO Biotech Inc | 46.6M | -0.5x | --- |
CalciMedica Inc | 46.5M | -2.2x | --- |
OKYO Pharma Ltd | 35.5M | -1.5x | --- |
Vicapsys Life Sciences Inc | 48.4M | -44.5x | --- |
Actinium Pharmaceuticals Inc | 45.2M | -1.0x | --- |
Gain Therapeutics Inc | 44.7M | -1.5x | --- |
Company Information
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Contact Information
- Headquarters
- Ole Maaloes Veh 3COPENHAGEN, Denmark 2200
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Peter Hirth
- President, Chief Executive Officer, Founder, Director
- Mai-Britt Zocca
- Chief Financial Officer
- Amy Sullivan
- Chief Accounting Officer
- Brian Burkavage
- Chief Scientific Officer
- Muhammad Al-hajj
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $46.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 65.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.37 |
Book Value | $2.02 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
